Current Opinion in Toxicology最新文献_第4页

Recent applications of physiologically based pharmacokinetic modeling to assess the toxicity of mixtures: A review 基于生理学的药代动力学模型在混合物毒性评估中的应用综述

IF 4.6

Current Opinion in Toxicology Pub Date : 2023-06-01 DOI: 10.1016/j.cotox.2023.100390

Harvey Clewell, Jerry Campbell, Matthew Linakis

{"title":"Recent applications of physiologically based pharmacokinetic modeling to assess the toxicity of mixtures: A review","authors":"Harvey Clewell, Jerry Campbell, Matthew Linakis","doi":"10.1016/j.cotox.2023.100390","DOIUrl":"10.1016/j.cotox.2023.100390","url":null,"abstract":"<div><p><span>In this article, we review recent research in the application of PBPK modeling to chemical mixtures, focusing on the previous three years. The scope of the review included both isozyme-specific modeling of drug–drug interactions and modeling of complex environmental mixtures. Recent pharmaceutical-related modeling efforts continue to advance the state of the art for predicting both pharmacokinetic and </span>pharmacodynamic interactions. In contrast, recent studies on modeling of environmental mixtures have often assumed that the human exposures are too low to drive metabolic interactions, and evaluations of complex mixtures have shifted focus to assessing the potential for PD interactions. Future progress in this area is hindered by the fact that the available PBPK platforms for modeling drug–drug interactions are not designed to support interaction modeling for more than two compounds. While this limitation may not be of concern for pharmaceuticals, it severely limits potential applications to environmental mixtures. Widespread application of PBPK interaction modeling to complex mixtures will require the development of user-friendly, web-based applications that allow individuals from a wide variety of disciplines to exercise the models. The Open Systems Pharmacology suite (PK-Sim and Mobi) may provide a useful platform for this purpose.</p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"34 ","pages":"Article 100390"},"PeriodicalIF":4.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46961531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of prenatal exposure to arsenic on T cell development in children 产前砷暴露对儿童T细胞发育的影响

IF 4.6

Current Opinion in Toxicology Pub Date : 2023-06-01 DOI: 10.1016/j.cotox.2023.100389

Rubhana Raqib, Evana Akhtar, Md. Ahsanul Haq, Protim Sarker

引用次数: 0

Advances in PAH mixture toxicology enabled by zebrafish 斑马鱼多环芳烃混合物毒理学研究进展

IF 4.6

Current Opinion in Toxicology Pub Date : 2023-06-01 DOI: 10.1016/j.cotox.2023.100392

Lindsay B. Wilson , Ian L. Moran , Kim A. Anderson , Robyn L. Tanguay

{"title":"Advances in PAH mixture toxicology enabled by zebrafish","authors":"Lindsay B. Wilson , Ian L. Moran , Kim A. Anderson , Robyn L. Tanguay","doi":"10.1016/j.cotox.2023.100392","DOIUrl":"10.1016/j.cotox.2023.100392","url":null,"abstract":"<div><p>Polycyclic aromatic hydrocarbons (PAHs) are a class of organic compounds produced by a variety of petrogenic and pyrogenic sources. PAHs inherently occur in the environment in complex mixtures. The early life-stage zebrafish model is a valuable tool for high-throughput screening (HTS) for toxicity of complex chemical mixtures due to its rapid development, high fecundity, and superb sensitivity to chemical insult. Zebrafish are amenable to exposure to surrogate mixtures as well as extracts of environmental samples and effect-directed analysis. In addition to its utility to HTS, the zebrafish has proven an excellent model for assessing chemical modes of action and identifying molecular initiating and other key events in an Adverse Outcome Pathway framework. Traditional methods of assessing PAH mixture toxicity prioritize carcinogenic potential and lack consideration of non-carcinogenic modes of action, assuming a similar molecular initiating event for all PAHs. Recent work in zebrafish has made it clear that while PAHs belong to the same chemical class, their modes of action can be divergent. Future research should use zebrafish to better classify PAHs by their bioactivity and modes of action to better understand mixture hazards.</p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"34 ","pages":"Article 100392"},"PeriodicalIF":4.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10085996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovating human chemical hazard and risk assessment through an holistic approach 通过整体方法创新人类化学危害和风险评估

IF 4.6

Current Opinion in Toxicology Pub Date : 2023-03-01 DOI: 10.1016/j.cotox.2023.100386

Aldert H. Piersma, Harm Heusinkveld, Ellen Hessel, Anne Kienhuis

引用次数: 0

Neurodegeneration in a regulatory context: The need for speed 调节环境下的神经退化:对速度的需求

IF 4.6

Current Opinion in Toxicology Pub Date : 2023-03-01 DOI: 10.1016/j.cotox.2022.100383

Julia J. Meerman , Gerrit Wolterink , Ellen V.S. Hessel , Esther de Jong , Harm J. Heusinkveld

引用次数: 1

Nephrotoxicity of marketed antisense oligonucleotide drugs 市售反义寡核苷酸药物的肾毒性

IF 4.6

Current Opinion in Toxicology Pub Date : 2022-12-01 DOI: 10.1016/j.cotox.2022.100373

Hangyu Wu , Aniket Wahane , Feryal Alhamadani , Kristy Zhang , Rajvi Parikh , SooWan Lee , Evan M. McCabe , Theodore P. Rasmussen , Raman Bahal , Xiao-bo Zhong , José E. Manautou

{"title":"Nephrotoxicity of marketed antisense oligonucleotide drugs","authors":"Hangyu Wu , Aniket Wahane , Feryal Alhamadani , Kristy Zhang , Rajvi Parikh , SooWan Lee , Evan M. McCabe , Theodore P. Rasmussen , Raman Bahal , Xiao-bo Zhong , José E. Manautou","doi":"10.1016/j.cotox.2022.100373","DOIUrl":"10.1016/j.cotox.2022.100373","url":null,"abstract":"<div><p>The field of antisense oligonucleotide<span> (ASO)-based therapies have been making strides in precision medicine due to their potent therapeutic application. Early successes in treating some genetic diseases are now attributed to an emerging class of antisense drugs. After two decades, the US Food and Drug Administration (FDA) has approved a considerable number of ASO drugs, primarily to treat rare diseases with optimal therapeutic outcomes. However, safety is one of the biggest challenges to the therapeutic utility of ASO drugs. Due to patients' and health care practitioners' urgent demands for medicines for untreatable conditions, many ASO drugs have been approved. However, a complete understanding of the mechanisms of adverse drug reactions<span><span> (ADRs) and toxicities of ASOs still need to be resolved. The range of ADRs is unique to a specific drug, while few ADRs are common to a section of drugs as a whole. Nephrotoxicity is an important concern that needs to be addressed considering the clinical translation of any drug candidates ranging from </span>small molecules to ASO-based drugs. This article encompasses what is known about the nephrotoxicity of ASO drugs, the potential mechanisms of action(s), and recommendations for future investigations on the safety of ASO drugs.</span></span></p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"32 ","pages":"Article 100373"},"PeriodicalIF":4.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9564916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Erratum to “regarding missing Editorial Disclosure statements in previously published articles”–Part I “关于先前发表的文章中缺失的编辑披露声明”的勘误表-第一部分

IF 4.6

Current Opinion in Toxicology Pub Date : 2022-12-01 DOI: 10.1016/j.cotox.2022.100375

引用次数: 0

Editorial overview: New cause for concern–Emerging nephrotoxicants and mechanisms of renal injury 编辑概述:关注的新原因——新出现的肾毒物和肾损伤的机制

IF 4.6

Current Opinion in Toxicology Pub Date : 2022-12-01 DOI: 10.1016/j.cotox.2022.100374

Lauren M. Aleksunes, Gary O. Rankin, José E. Manautou

引用次数: 0

Drugs of abuse and kidney toxicity 滥用药物和肾毒性

IF 4.6

Current Opinion in Toxicology Pub Date : 2022-12-01 DOI: 10.1016/j.cotox.2022.100360

João P. Silva , Helena Carmo , Félix Carvalho

引用次数: 0

Natural products for the prevention of antibiotic-associated kidney injury 预防抗生素相关肾损伤的天然产物

IF 4.6

Current Opinion in Toxicology Pub Date : 2022-12-01 DOI: 10.1016/j.cotox.2022.100363

Marshall Yuan , Kelsey Briscese , Thomas S. Hong , Luigi Brunetti

{"title":"Natural products for the prevention of antibiotic-associated kidney injury","authors":"Marshall Yuan , Kelsey Briscese , Thomas S. Hong , Luigi Brunetti","doi":"10.1016/j.cotox.2022.100363","DOIUrl":"10.1016/j.cotox.2022.100363","url":null,"abstract":"<div><p>Drug-induced acute kidney injury<span> (AKI), especially from exposure to antibiotics, has a high prevalence secondary to their frequent prescription. Typically, drug-induced AKI results from acute tubular necrosis<span> or acute interstitial nephritis<span>. While some risk factors for the development of AKI in individuals treated with antibiotics are modifiable, others such as concomitant drug<span><span> therapies to treat comorbidities, age, and pre-existing chronic kidney disease are not modifiable. As such, there is an urgent need to identify strategies to reduce the risk of AKI in individuals requiring antibiotic therapy. Natural products, especially those rich in active constituents possessing antioxidant properties are an attractive option to mitigate AKI risk. Given that mitochondrial dysfunction precedes AKI and natural products can restore mitochondrial health and counter the </span>oxidative stress secondary to mitochondrial damage investigating their utility warrants further attention. The following review summarizes the available preclinical and clinical evidence that provides a foundation for future study.</span></span></span></span></p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"32 ","pages":"Article 100363"},"PeriodicalIF":4.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46717274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0